• DOI:10.1111/dth.13379
Corpus ID: 215748750

5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

@article{Dhurat20205AlphaRI,
  title={5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety},
  author={R. Dhurat and A. Sharma and L. Rudnicka and G. Kroumpouzos and M. Kassir and H. Galadari and U. Wollina and T. Lotti and Masa Golubovic and I. Binic and S. Grabbe and M. Goldust},
  journal={Dermatologic Therapy},
  year={2020},
  volume={33}
}

R. Dhurat, A. Sharma, +9 authors M. Goldust

Published 2020

Medicine

Dermatologic Therapy

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5‐alpha reductase (5‐AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5‐alpha reductase inhibitor (5‐ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT… CONTINUE READING

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed